Man claims to have been assaulted by a two-wheeler rider near Zydus Bridge in Ahmedabad, allegedly involving traffic police.
A 45-year-old businessman, Himanshu Dineshbhai Shah, has filed a complaint with the Vastrapur police alleging that he was assaulted by an unidentified Activa rider and traffic police personnel during a roadside altercation near the Zydus Bridge last month. The incident occurred on November 12 when Shah was driving with his younger brother towards Gandhinagar. As they stopped at a non-operational traffic signal under the bridge, an Activa rider behind them began honking repeatedly, prompting Shah to move his car aside.
The rider allegedly continued to hurl abuses, and Shah followed him, confronting him and asking why he was using abusive language. The exchange escalated into a physical altercation, and Shah claimed that Traffic Police Constable Chandrasinh Chavda, along with a home guard and Traffic Response Brigade (TRB) personnel, intervened and began beating him with lathis instead of separating the parties involved.
Shah alleged that the officers took him aside, made him sit at their post, and later took all parties into custody after a bystander called the emergency number 100. Shah sought medical treatment the next morning and was admitted to SVP Hospital for 24 hours due to injuries sustained in the incident. On December 9, he submitted a formal written complaint reiterating the events and naming the unknown Activa rider, Constable Chandrasinh Chavda, and other unidentified TRB and home guard personnel.
The Vastrapur police have initiated an inquiry to determine the sequence of events, the conduct of the traffic personnel, and the identity of the Activa rider. The police will take further action based on the findings. Shah’s brother, Ummagbhai Shah, has been listed as a witness in the complaint. The incident has raised questions about the behavior of traffic police personnel and their handling of roadside altercations. The police investigation is ongoing, and it remains to be seen what action will be taken against the accused parties.
A widely used blood pressure medication has been recalled due to concerns of potential contamination with a different pharmaceutical compound.
Glenmark Pharmaceuticals Inc. has issued a recall of over 11,100 bottles of its blood pressure medication, Ziac, due to potential cross-contamination with another drug. The medication, which is used to treat high blood pressure, also known as hypertension, may contain ezetimibe, a drug used to treat high cholesterol. The recall was initiated after testing of reserve samples revealed the presence of ezetimibe.
The affected pills come in 2.5mg and 6.25mg doses and are packaged in 30-count, 100-count, and 500-count bottles. The recall includes specific lot numbers with expiration dates ranging from November 2025 to May 2026. According to the Food and Drug Administration (FDA), the recall is classified as Class III, meaning that the use or exposure to the product is not likely to cause adverse health consequences.
Bisoprolol/hydrochlorothiazide, the active ingredients in Ziac, work by blocking beta-1 receptors in the heart, allowing it to return to a regular heartbeat. The medication is commonly used to treat high blood pressure, a condition that affects millions of people worldwide.
The FDA has not provided guidance on what patients should do if their medication is affected by the recall. The Independent has reached out to the FDA and Glenmark Pharmaceuticals for comment, but so far, no further information has been provided. Patients who are taking Ziac and are concerned about the recall should consult with their healthcare provider or pharmacist for advice on what to do next.
The recall highlights the importance of ensuring the quality and safety of pharmaceutical products. Cross-contamination can occur during the manufacturing process, and it is crucial for pharmaceutical companies to have rigorous testing and quality control measures in place to prevent such incidents. The FDA and pharmaceutical companies must work together to ensure that medications are safe and effective for patients to use.
Hypertension Alert: Beyond Genetics and Sodium Intake, Expert from Apollo Uncovers Common Daily Habits Linked to Increased Blood Pressure Risk
A senior neurologist from Apollo Hospitals, Dr. Sudhir Kumar, has highlighted the importance of everyday habits in contributing to high blood pressure. While high-sodium diets and family history are well-known risk factors, Dr. Kumar emphasizes that routine behaviors, often overlooked, can gradually push blood pressure upwards. He notes that hypertension is shaped by cumulative behavior rather than isolated choices, and that ordinary habits can trigger physiological changes that impact cardiovascular health.
Dr. Kumar identifies several daily actions that can elevate blood pressure over time, including stressful driving, exercising outdoors on polluted days, long working hours, sedentary patterns, and constant pressure. He also highlights the importance of social well-being and sleep, noting that loneliness, weak social support systems, and disrupted sleep patterns can contribute to higher cardiovascular risk.
In addition, Dr. Kumar warns against diet triggers such as excessive sugar intake, high caffeine consumption, and alcohol, as well as packaged foods that contain hidden sodium. He also emphasizes the importance of regular exercise and avoiding smoking and second-hand smoke, which can cause immediate spikes in blood pressure and contribute to long-term artery damage.
The key takeaway from Dr. Kumar’s advisory is that hypertension develops gradually and is shaped by routine habits, not sudden events. He urges individuals to assess their daily routines, identify their triggers, and make incremental changes to protect heart health over the long term. By doing so, individuals can reduce their risk of developing hypertension and promote overall cardiovascular well-being.
Some of the key habits that Dr. Kumar recommends avoiding or modifying include:
* Stressful driving and exercising on polluted days
* Long working hours and sedentary patterns
* Excessive sugar intake, high caffeine consumption, and alcohol
* Packaged foods with hidden sodium
* Smoking and second-hand smoke
* Disrupted sleep patterns and loneliness
By making small changes to daily habits and being mindful of these potential triggers, individuals can take a proactive approach to protecting their heart health and reducing their risk of developing hypertension. As Dr. Kumar notes, “Blood pressure does not rise overnight; it is shaped by daily habits. Identify your triggers, fix one behavior at a time, and your arteries will thank you.”
Alkem Laboratories Sets Up Investor and Analyst Conferences for December 2025
Alkem Laboratories, a leading Indian pharmaceutical company, has announced that it will be hosting analyst and investor meetings in December 2025. The meetings are scheduled to take place on December 10th and 11th, 2025, and will provide a platform for the company’s management team to engage with analysts and investors, discussing the company’s performance, strategy, and future growth prospects.
During the meetings, Alkem Laboratories’ management team, led by the company’s Managing Director, Sandeep Singh, will present an overview of the company’s business, highlighting its achievements and milestones over the past year. The team will also provide an update on the company’s current projects and initiatives, including its research and development pipeline, manufacturing capabilities, and marketing strategies.
The meetings will also provide an opportunity for analysts and investors to ask questions and engage in discussions with the management team, gaining a deeper understanding of the company’s operations and future plans. This interaction will enable them to make informed investment decisions and provide accurate analysis of the company’s prospects.
Alkem Laboratories has been performing well in recent years, driven by its strong product portfolio, robust manufacturing capabilities, and expanding global presence. The company has a diverse range of products, including anti-infectives, gastro-intestinal, and pain management drugs, which are sold in over 50 countries worldwide. Its manufacturing facilities are located in India and the United States, and are compliant with international regulatory standards.
The company’s research and development pipeline is also robust, with several new products in various stages of development. Alkem Laboratories has a strong focus on innovation, and is committed to developing new and innovative products to meet the evolving needs of patients and healthcare providers.
The analyst and investor meetings are expected to provide valuable insights into Alkem Laboratories’ future growth prospects and strategies. The company’s management team is expected to outline its plans for expanding its product portfolio, increasing its global presence, and driving growth through innovation and strategic partnerships. Overall, the meetings will provide a platform for Alkem Laboratories to showcase its strengths and capabilities, and to demonstrate its commitment to delivering value to its stakeholders.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.